太平洋证券股份有限公司 关于青岛英派斯健康科技股份有限公司 2023 年度募集资金存放 与实际使用情况的专项核查意见 太平洋证券股份有限公司（以下简称"太平洋证券"或"保荐机构"）作为 青岛英派斯健康科技股份有限公司（以下简称"英派斯"或"公司"）承接持续 督导的保荐机构，根据《证券发行上市保荐业务管理办法》、《上市公司监管指 引第 2 号——上市公司募集资金管理和使用的监管要求（2022 年修订）》、《深 圳证券交易所股票上市规则（2023 年 8 月修订）》、《深圳证券交易所上市公司 自律监管指引第 1 号——主板上市公司规范运作（2023 年 12 月修订）》等有关 规定，对英派斯 2023 年度募集资金存放与使用情况进行了审慎核查，核查情况 及核查意见如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 经中国证券监督管理委员会《关于核准青岛英派斯健康科技股份有限公司 首次公开发行股票的批复》（证监许可[2017]1539 号）核准，青岛英派斯健康科 技股份有限公司向社会公开发行人民币普通股（A 股）30,000,000 股，每股面 值 1 元，每股发行价格 16.05 元，募集资金总额 ...

证券代码：002899 证券简称：英派斯 公告编号：2024-037 青岛英派斯健康科技股份有限公司 关于增加注册资本并修订《公司章程》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 青岛英派斯健康科技股份有限公司（以下简称"公司"）于 2024 年 4 月 26 日召开的第三届董事会 2024 年第四次会议，审议通过了《关于增加注册资本并 修订<公司章程>的议案》。具体情况如下： 三、授权事宜 根据公司 2022 年第二次临时股东大会审议通过的《关于提请股东大会授权 董事会及其授权人士全权办理本次非公开发行 A 股股票的相关事宜的议案》， 公司股东大会授权董事会及其授权人士在相关法律法规、规章及其他规范性文件 的范围内全权依据本次发行情况，增加公司注册资本、对公司章程有关条款进行 修改，并报有关政府部门和监管机构核准或备案，办理工商变更登记事宜。 根据公司 2023 年第二次临时股东大会审议通过的《关于提请股东大会延长 授权董事会及其授权人士全权办理本次向特定对象发行 A 股股票相关事项有效 期的议案》，股东大会将授权有效期自前次授权有效期届满之日（ ...

青岛英派斯健康科技股份有限公司 非经营性资金占用及其他关联资金 往来情况的专项审计说明 和信专字（2024）第 000220 号 | 目 录 | 页 | 码 | | --- | --- | --- | | 一、非经营性资金占用及其他关联资金往来情况的专项审计说明 | 1-2 | | | 二、非经营性资金占用及其他关联资金往来情况汇总表 | 3 | | 和信会计师事务所（特殊普通合伙） 二〇二四年四月二十六日 非经营性资金占用及其他关联资金 往来情况的专项审计说明 和信专字（2024）第 000220 号 依据中国证券监督管理委员会《上市公司监管指引第 8 号——上市公司资金 往来、对外担保的监管要求》（证监会公告[2022]26 号），及深圳证券交易所《深 圳证券交易所上市公司自律监管指南第 1 号——业务办理》的要求，英派斯编制 了本专项审计说明后附的 2023 年度非经营性资金占用及其他关联资金往来情况 汇总表（以下简称"汇总表"）。如实编制汇总表并确保其真实、合法、完整是英派 斯管理层的责任；我们的责任是对上述汇总表进行审核，并出具专项说明。 青岛英派斯健康科技股份有限公司全体股东： 我们接受委托，按照 ...

青岛英派斯健康科技股份有限公司 董事会审计委员会对会计师事务所2023年度 履职情况评估及履行监督职责情况的报告 2023 年，青岛英派斯健康科技股份有限公司（以下简称公司）董事会审计 委员会根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司 治理准则》《国有企业、上市公司选聘会计师事务所管理办法》《上市公司独立董 事管理办法》《深圳证券交易所上市公司自律监管指引第1号——主板上市公司规 范运作》和《公司章程》《董事会审计委员会工作细则》等规定和要求，本着 勤勉尽责的原则，充分发挥董事会审计委员会的专业职能和监督作用。现将董 事会审计委员会对会计师事务所2023年度履职评估及履行监督职责的情况汇报 如下： 一、2023年年审会计师事务所基本情况 （一）会计师事务所基本情况 和信会计师事务所（特殊普通合伙）（以下简称和信所）1987 年 12 月成立（转 制特殊普通合伙时间为 2013 年 4 月 23 日），注册地址为济南市文化东路 59 号盐业 大厦七楼，首席合伙人为王晖先生，拥有财政部颁发的会计师事务所执业证书。和 信所 2023 年末合伙人数量为 37 位，年末注册会计师人数为 262 人， ...

一、基本情况 （一）背景 青岛英派斯健康科技股份有限公司于 2024 年 3 月 12 日召开的第三届董事 会 2024 年第二次会议及第三届监事会 2024 年第二次会议审议通过了《关于使 用闲置自有资金进行现金管理的议案》，同意公司在确保不影响公司正常经营 的情况下，为进一步提高资金使用效率，使用最高额度不超过 20,000 万元人民 币的暂时闲置自有资金进行现金管理，用于购买安全性高、流动性好、风险较 低的理财产品。该事项自公司第三届董事会 2024 年第二次会议审议通过之日起 12 个月内可循环滚动使用。 根据公司经营情况和资金使用安排，在确保满足公司正常经营活动的资金 需求及风险可控的前提下，为了提高资金的使用效率，更好实现公司资产保值 增值，公司于 2024 年 4 月 26 日召开的第三届董事会 2024 年第四次会议及第三 届监事会 2024 年第三次会议审议通过了《关于调整使用闲置自有资金进行现金 管理额度及期限的议案》，同意公司在确保不影响正常经营的情况下，将闲置 自有资金进行现金管理的额度由不超过人民币 20,000 万元调整为不超过人民币 50,000 万元，使用期限调整为自本次董事会 ...

青岛英派斯健康科技股份有限公司 2023 年度独立董事述职报告 独立董事徐国君 本人作为青岛英派斯健康科技股份有限公司（以下简称"公司"）的独立董 事，严格按照《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》（以下简称"《证券法》"）、《上市公司独立董事管理办 法》、《上市公司独立董事履职指引》等有关法律、法规的规定以及《公司章程》、 《独立董事工作制度》的要求，本着恪尽职守、勤勉尽责的工作态度，认真行使 职权，及时了解公司的经营信息，全面关注公司的发展状况，按时出席了公司年 度内召开的历次会议，认真审议各项议案，为公司经营和发展提出合理化的意见 和建议，忠实履行了独立董事应尽的职责，切实发挥独立董事的职能作用，维护 了全体股东尤其是中小股东的合法权益。现将 2023 年度本人的履职情况报告如 下： 一、基本情况 （一）工作履历、专业背景以及兼职情况 本人徐国君，中国人民大学会计学专业研究生毕业，经济学博士学位，非执 业注册会计师，国务院政府特殊津贴专家。1983 年 9 月至 1985 年 8 月，在北京 林业部干部学院任教；1987 年 8 月至 1988 年 11 月，在北 ...

证券代码：英派斯 证券简称：002899 公告编号：2024-032 青岛英派斯健康科技股份有限公司 2023 年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 经中国证券监督管理委员会《关于核准青岛英派斯健康科技股份有限公司首 次公开发行股票的批复》（证监许可[2017]1539 号）核准，青岛英派斯健康科技 股份有限公司（以下简称"英派斯"或"公司"）向社会公开发行人民币普通股 （A 股）30,000,000 股，每股面值 1 元，每股发行价格 16.05 元，募集资金总额 人民币 481,500,000.00 元，扣除各项发行费用合计人民币 48,294,558.28 元，实际 募集资金净额为 433,205,441.72 元。截止 2017 年 9 月 11 日，实际募集资金净额 433,205,441.72 元已全部到位，上述募集资金到位情况已经山东和信会计师事务 所（特殊普通合伙）（现更名为和信会计师事务所（特殊普通合伙））出具和信 验字（2017）第 ...

证券代码：002899 证券简称：英派斯 公告编号：2024-041 青岛英派斯健康科技股份有限公司 会计政策变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 本次会计政策变更对公司财务状况、经营成果及现金流量不会产生重大影响。 青岛英派斯健康科技股份有限公司（以下简称"公司"）根据中华人民共和 国财政部（以下简称"财政部"）发布的《企业会计准则解释第 16 号》（财会 〔2022〕31 号）、《企业会计准则解释第 17 号》（财会〔2023〕21 号）的文件 要求变更会计政策。本次会计政策变更对公司财务状况、经营成果及现金流量不 会产生重大影响。根据《深圳证券交易所股票上市规则》等的相关规定，本事项 无需提交公司董事会及股东大会审议。现将具体情况公告如下： 一、会计政策变更概述 （一）会计政策变更的原因和变更日期 1、2022 年 11 月 30 日，财政部发布了《企业会计准则解释第 16 号》（财 会〔2022〕31 号)，要求"关于单项交易产生的资产和负债相关的递延所得税不 适用初始确认豁免的会计处理"的内容自 2023 年 1 月 ...

Financial Performance - The company's operating revenue for 2023 reached ¥895,319,626.89, representing an increase of 8.56% compared to ¥824,696,742.37 in 2022[18]. - The net profit attributable to shareholders for 2023 was ¥88,164,055.52, a significant increase of 34.26% from ¥65,664,553.48 in the previous year[18]. - The net profit after deducting non-recurring gains and losses was ¥85,070,020.18, which is a remarkable increase of 106.43% compared to ¥41,210,455.41 in 2022[18]. - The net cash flow from operating activities for 2023 was ¥260,016,466.70, showing a substantial growth of 149.05% from ¥104,403,463.45 in 2022[18]. - Basic earnings per share increased by 32.73% to CNY 0.73 from CNY 0.55 year-on-year[19]. - Total assets reached CNY 2,294,796,153, reflecting a 13.04% increase compared to CNY 2,029,945,060 at the end of 2022[19]. - Net assets attributable to shareholders rose by 6.95% to CNY 1,240,736,960 from CNY 1,160,132,904 year-on-year[19]. - Quarterly revenue for Q4 2023 was CNY 236,759,162.48, with total annual revenue showing a positive trend[24]. - The company reported a net cash flow from operating activities of CNY 79,509,517.49 in Q4 2023[24]. - The company achieved a total revenue of 895.32 million yuan in 2023, an increase of 8.56% compared to the previous year, and a net profit attributable to shareholders of 88.16 million yuan, up 34.26% year-on-year[45]. Market Expansion and Strategy - The company is actively exploring market expansion opportunities to increase its market share in the health technology sector[18]. - The company has established a nationwide sales network covering 34 provincial-level administrative regions and has successfully entered international markets in Europe and Asia-Pacific with its IMPULSE brand[34]. - The company is focusing on optimizing resource allocation, accelerating product development, and expanding consumer markets to enhance its overseas market strategy[46]. - The company is committed to a "second entrepreneurship" strategy, optimizing its business structure and enhancing collaboration among its domestic sales divisions[45]. - The company is focusing on new product and technology research and development to drive future growth[141]. - The company plans to expand its overseas brand business and increase export scale, focusing on high-value-added products and enhancing marketing capabilities in foreign markets[109]. Research and Development - The company has maintained its commitment to research and development, focusing on new products and technologies to enhance market competitiveness[18]. - The company is focused on developing innovative fitness equipment, including a multi-functional treadmill and a VR spinning bike, to enhance user experience and market competitiveness[76]. - R&D investment amounted to ¥41,087,475.49 in 2023, a 3.00% increase from ¥39,891,152.84 in 2022, representing 4.59% of operating revenue[76]. - The R&D personnel structure showed a notable change, with a 24.19% increase in the number of bachelor's degree holders in R&D[76]. - The company has a total of 314 valid domestic patents, including 31 invention patents, 197 utility model patents, and 86 design patents, along with 2 foreign patents[56]. Environmental Responsibility - Qingdao Inpaiss Health Technology Co., Ltd. reported a total of 1.45 tons of particulate matter emissions, with a concentration of 3.5 mg/m³, meeting the emission standards[171]. - The company achieved a total wastewater discharge of 0.174 tons with a chemical oxygen demand (COD) of 60 mg/L, complying with the urban sewage discharge standards[171]. - The company has established emergency response plans for environmental incidents, which have been reviewed and filed with local ecological environment departments[172]. - Qingdao Inpaiss has increased its environmental protection investments and adheres to green development principles, actively reducing operational impacts on the environment[173]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[175]. Corporate Governance - The company maintains strict compliance with information disclosure regulations, ensuring timely and accurate communication with investors[121]. - The company has established a transparent performance evaluation and incentive mechanism for senior management to align interests among shareholders, the company, and management[120]. - The board of directors held a total of 12 meetings during the reporting period, with attendance rates varying among members[145]. - The company has established a robust internal management structure that operates independently from its controlling shareholders[124]. - The company has not reported any significant related party transactions or competition with its controlling shareholders[125]. Shareholder Commitments - The company reported a commitment to not transfer or entrust management of shares for 36 months from the date of listing, with a maximum annual transfer limit of 25% of total shares held during the tenure of directors and senior management[183]. - The company has committed to not selling more than 50% of its shares through public trading within 12 months after resignation, ensuring stability in shareholding[183]. - The company will announce any share reduction three trading days in advance, ensuring transparency in its shareholding activities[184]. - The company has a long-term commitment to fulfill shareholding promises made during the IPO process, ensuring compliance with regulations[184]. Employee Management - The total number of employees at the end of the reporting period was 1,509, with 941 in the parent company and 568 in major subsidiaries[155]. - The company has established a comprehensive performance evaluation and compensation management system, linking salaries to work performance[157]. - The company has a training plan based on the ISO10015 training system to enhance employee skills and overall quality[158]. - The company has implemented measures to ensure employee rights and safety, including regular health check-ups and improvements to working conditions[176]. Future Outlook - The company provided guidance for the next fiscal year, projecting a revenue growth of 10% to 1.32 billion RMB[135]. - The management emphasized a commitment to sustainability, aiming to reduce operational carbon emissions by 15% by 2025[190]. - The company has outlined a strategic goal to achieve a compound annual growth rate (CAGR) of 12% over the next five years[190]. - Overall, the management remains optimistic about future growth, citing strong demand and a robust pipeline of new products[135].

Financial Performance - The company's revenue for Q1 2024 was CNY 238,399,460.98, representing a 19.86% increase compared to CNY 198,895,446.90 in the same period last year[5] - Net profit attributable to shareholders reached CNY 13,884,833.93, a significant increase of 313.80% from CNY 3,355,449.08 in the previous year[5] - The net profit after deducting non-recurring gains and losses was CNY 12,909,457.36, up 868.04% from CNY 1,333,568.87 year-on-year[5] - The company's basic and diluted earnings per share were both CNY 0.12, reflecting a 300.00% increase from CNY 0.03 in the same quarter last year[5] - The total comprehensive income for Q1 2024 was CNY 13,884,833.93, significantly higher than CNY 3,355,449.08 in Q1 2023, marking an increase of approximately 314%[24] - The operating profit for Q1 2024 was CNY 15,898,094.07, compared to CNY 4,506,402.64 in Q1 2023, indicating an increase of approximately 253%[23] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,395,913,810.71, a 4.41% increase from CNY 2,294,796,153.51 at the end of the previous year[5] - The total liabilities increased to ¥1,156,631,212.14 from ¥1,054,059,193.02, representing a rise of 9.73%[20] - The company reported a significant increase in accounts receivable, which rose by 42.04% to CNY 154,355,627.93 from CNY 108,668,089.35 year-on-year[9] - The company experienced a 100.83% increase in prepayments, totaling CNY 22,445,516.25, compared to CNY 11,176,235.06 in the previous year[9] Cash Flow - The net cash flow from operating activities was negative CNY 31,734,064.67, a decline of 144.31% compared to a positive CNY 71,624,760.12 in the same period last year[5] - The cash and cash equivalents at the end of Q1 2024 stood at CNY 238,864,787.99, a decrease from CNY 540,571,941.51 at the end of Q1 2023[25] - The company reported a net cash outflow from investing activities of CNY -125,137,112.65, compared to a smaller outflow of CNY -44,525,938.90 in the previous year[25] - The company experienced a cash inflow from financing activities of CNY 57,950,870.87, down from CNY 142,799,652.77 in the same quarter last year[25] Shareholder Information - The company repurchased a total of 1,256,700 shares, accounting for 1.05% of the total share capital as of the end of the reporting period[12] - The largest shareholder, Hainan Jiangheng Industrial Investment Co., Ltd., holds 33.89% of the shares, with 19,466,200 shares pledged[11] - The company has 12,985 common stock shareholders at the end of the reporting period[11] - The company has no preferred shareholders or related party transactions among the top shareholders[12] Other Significant Events - The company has completed the registration of its wholly-owned subsidiary, Shenzhen Yingpais Sports Technology Co., Ltd., on April 11, 2024[16] - The company is involved in a labor arbitration case with a claim amount of RMB 174,800, which is currently under appeal[14] - The company has not disclosed any significant changes in the top 10 shareholders or their participation in margin trading[12] - The company has not formed any expected liabilities from ongoing litigation as of the reporting date[14] Research and Development - The company reported a significant increase in research and development expenses, which rose to ¥13,280,460.18 from ¥10,828,798.91, reflecting a growth of 22.61%[21]